BCG · M&A · Medium · Clinical diagnostics · Voice-ready

Ridgeview–SignalDx Deal

Ridgeview Diagnostics is a 16-site clinical lab group with $228M of revenue. It is considering SignalDx, a 94-person specialty genetics lab with $44M of revenue and 19% EBITDA. The board needs a go/no-go and bid range, with payer novation and specialist retention treated as conditions rather than footnotes.

CoachNed is Ned’s independent project. It is not affiliated with Deloitte, McKinsey, BCG, Bain, or any other firm named here for interview-style practice. The cases on this site are AI-simulated.